Kirsti Näntö-Salonen Selected Research

Phenylketonurias (Phenylketonuria)

1/2009	[Phenylketonuria].
8/2005	Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kirsti Näntö-Salonen Research Topics

Disease

11	Lysinuric Protein Intolerance 01/2017 - 07/2003
9	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2020 - 02/2004
4	Hyperammonemia 01/2016 - 07/2003
3	Pulmonary Alveolar Proteinosis 01/2017 - 03/2012
3	Anemia 03/2012 - 02/2006
3	Hyperinsulinism (Hyperinsulinemia) 08/2006 - 08/2004
2	Disease Progression 01/2019 - 01/2018
2	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 10/2015
2	Failure to Thrive 01/2016 - 03/2012
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2016 - 06/2007
2	Phenylketonurias (Phenylketonuria) 01/2009 - 08/2005
2	Diarrhea 02/2007 - 07/2003
2	Hypoglycemia (Reactive Hypoglycemia) 08/2006 - 08/2004
1	Glucose Intolerance 01/2017
1	Respiratory Insufficiency (Respiratory Failure) 01/2017
1	Fibrosis (Cirrhosis) 01/2016
1	Malnutrition (Nutritional Deficiencies) 01/2016
1	Disease Susceptibility (Diathesis) 06/2011
1	Hyperlipidemias (Hyperlipidemia) 12/2010
1	Atrophy 01/2010
1	Renal Insufficiency (Renal Failure) 04/2008
1	Muscle Weakness 04/2008
1	Osteoporosis 06/2007
1	Hepatolenticular Degeneration (Wilson's Disease) 03/2006
1	Toxemia 02/2006
1	Congenital Adrenal Hyperplasia (Hyperplasia, Congenital Adrenal) 09/2005
1	Medium chain acyl CoA dehydrogenase deficiency 08/2005
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 08/2005
1	Hyperplasia 08/2005
1	Seizures (Absence Seizure) 08/2004
1	Type 2 Diabetes Mellitus (MODY) 08/2004
1	Congenital Hyperinsulinism 08/2004
1	Infections 02/2004

Drug/Important Bio-Agent (IBA)

8	Amino Acids FDA Link 01/2017 - 02/2007
7	AutoantibodiesIBA 11/2020 - 11/2008
5	Proteins (Proteins, Gene)FDA Link 01/2016 - 07/2003
4	Arginine (L-Arginine)FDA Link 10/2015 - 07/2003
4	Insulin (Novolin)FDA Link 06/2011 - 08/2004
3	Basic Amino Acid Transport SystemsIBA 10/2015 - 07/2003
3	Lysine (L-Lysine)FDA Link 12/2010 - 07/2003
3	OrnithineIBA 12/2010 - 07/2003
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2017
2	LipidsIBA 01/2016 - 12/2008
2	Carnitine (L-Carnitine)FDA LinkGeneric 04/2008 - 06/2007
2	Dihydroxyphenylalanine (Dopa)IBA 08/2006 - 01/2006
1	IntegrinsIBA 11/2020
1	CC ChemokinesIBA 11/2020
1	Chemokine ReceptorsIBA 01/2019
1	Apoptosis Regulatory ProteinsIBA 01/2019
1	SteroidsIBA 01/2017
1	sargramostim (Leukine)FDA Link 01/2017
1	Blood Glucose (Blood Sugar)IBA 01/2012
1	Growth Hormone (Somatotropin)IBA 01/2011
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2010
1	pimecrolimus (Elidel)FDA Link 01/2010
1	SodiumIBA 01/2010
1	HLA-DQB1 antigen (HLA DQB1)IBA 11/2008
1	AmmoniaIBA 04/2008
1	Erythropoietin FDA Link 06/2007
1	IronIBA 06/2007
1	CopperIBA 03/2006
1	Diamino Amino AcidsIBA 02/2006
1	Flutamide (Eulexin)FDA LinkGeneric 09/2005
1	G(A1) ganglioside (GA(1))IBA 08/2005
1	Long-Chain-3-Hydroxyacyl-CoA DehydrogenaseIBA 08/2005
1	GlucokinaseIBA 08/2004
1	Hypoglycemic Agents (Hypoglycemics)IBA 08/2004
1	Diazoxide (Hyperstat)FDA Link 08/2004
1	Neutralizing AntibodiesIBA 02/2004
1	Peptides (Polypeptides)IBA 02/2004
1	EpitopesIBA 02/2004
1	HLA-DR Antigens (HLA-DR)IBA 02/2004
1	CitrullineIBA 07/2003
1	Urea (Carbamide)FDA LinkGeneric 07/2003

Therapy/Procedure

3	Therapeutics 01/2018 - 01/2009
2	Pancreatectomy 08/2006 - 08/2004
1	Immunotherapy 01/2019
1	Kidney Transplantation 01/2016
1	Secondary Prevention 12/2010
1	Cholecystectomy 08/2006
1	Choledochostomy 08/2006
1	Aftercare (After-Treatment) 08/2004